Results 121 to 130 of about 2,522,370 (217)

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

open access: yesActa Ophthalmologica, Volume 104, Issue 6, Page e630-e647, September 2026.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen   +3 more
wiley   +1 more source

A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma

open access: yes, 2017
Muhammad Omer Jamil, Mary S Jerome, Deborah Miley, Katri S Selander, Francisco Robert Division of Hematology and Oncology, Department of Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA ...
Jamil MO   +4 more
core  

Influence of zoledronic acid and pamidronate on tooth eruption in children with osteogenesis imperfecta

open access: yes
Introduction: Osteogenesis imperfecta (OI) is a congenital disease comprising a heterogeneous group of inherited connective tissue disorders. The main treatment in children is bisphosphonate therapy.
Nova García, Manuel Joaquín De   +3 more
core   +1 more source

Expanding Spectrum of FIG4‐Related Neurological Disorders of Lysosomal Homeostasis: Case Report and Overview of the Potential Genotype–Phenotype Correlations

open access: yesClinical Genetics, Volume 110, Issue 3, Page 363-368, September 2026.
FIG4 is essential for lysosomal homeostasis. FIG4‐related disorders present as a continuous spectrum from the juvenile lethality in Yunis‐Varon syndrome to an increased risk of amyotrophic lateral sclerosis (ALS) in adult life. FIG4‐related disorders comprise a novel group of disorders of lysosomal homeostasis and can be classified into severe ...
Pankaj Prasun, Matthew Rasberry
wiley   +1 more source

Hypophosphataemia following iron infusion: a narrative review of an increasingly recognised complication

open access: yesInternal Medicine Journal, Volume 56, Issue 9, Page 1500-1509, September 2026.
Abstract Parenteral iron is widely prescribed by medical practitioners, with more than 600 000 outpatient prescriptions dispensed in 2025 through the Australian Pharmaceutical Benefits Scheme. While intravenous iron has transformed the management of iron deficiency, hypophosphataemia is now recognised as a common complication, with incidences reported ...
Brenda Ta   +3 more
wiley   +1 more source

Patterns of Osteoporosis Treatment Initiation Following Low‐Trauma Fracture: A Population‐Based Retrospective Cohort Study in New South Wales, Australia, Using Linked Administrative Health Data

open access: yesMedical Journal of Australia, Volume 224, Issue 9, September 2026.
ABSTRACT Objectives To characterise osteoporosis medicine prescribing patterns following low‐trauma fractures and identify predictors of early treatment initiation. Study Type Retrospective population‐based cohort study. Setting New South Wales, Australia, using statewide linked administrative health data.
Mike Lin   +5 more
wiley   +1 more source

Zoledrinic Acid Induces Steoblastic Differentiation of Mesenchymal Stem Cells without Change in Hypomethylation Status of OSTERIX Promoter [PDF]

open access: yesCell Journal, 2012
Objective: Mechanism of zoledronic acid on osteoblastic differentiation of mesenchymal stem cells (MSCs) has not fully understood. With the knowledge of some drugs mechanism that alter methylation pattern of some genes, the present research sets out to ...
Maryam Mahmodinia Maymand   +5 more
doaj  

Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis

open access: yes, 2012
Akshara Richhariya1, Yi Qian2, Yufan Zhao2, Karen Chung11Amgen Inc, Global Health Economics, Thousand Oaks, CA, USA; 2Amgen Inc, Global Biostatistical Sciences, Thousand Oaks, CA, USAPurpose: Intravenous (IV) zoledronic acid (ZA) is commonly used to ...
Richhariya A, Qian Y, Chung K, Zhao Y
core  

Zoledronic acid in the management of metastatic bone disease

open access: yesTherapeutics and Clinical Risk Management, 2008
Thomas J Polascik, Vladimir MouravievDuke Prostate Center and Division of Urologic Surgery, Duke University Medical Center, Durham, NC, USAAbstract: Many patients with advanced cancer experience decreased bone strength due to metastatic foci, underlying ...
Thomas J Polascik, Vladimir Mouraviev
doaj  

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

open access: yes, 2002
peer reviewedBisphosphonate drugs inhibit osteoclastic bone resorption and are widely used to treat skeletal complications in patients with tumor-induced osteolysis.
Bonjean, Karine   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy